William D. Waddill, an insider of Protagonist Therapeutics, Inc. (PTGX), reported transactions in the company’s common stock that took place on June 23, 2026, under a prearranged Rule 10b5-1 trading plan adopted on February 27, 2026. The filing reports two key actions. Waddill exercised stock options covering 9,000 shares of Protagonist common stock at an exercise price of $16.54 per share. The filing notes that the stock options involved were fully vested. This option exercise corresponds to the acquisition of shares through an option transaction, typically reported with transaction code “M” on Form 4. On the same date, Waddill sold 16,825 shares of common stock at a weighted average sale price of $117.94 per share, a transaction generally reported with transaction code “S.” The shares were sold in multiple open-market transactions at prices ranging from $117.00 to $119.07 per share. Based on the weighted average price, the sale generated approximately $1.98 million in gross proceeds before commissions, taxes, or other costs. The filing states that the transactions were carried out pursuant to Waddill’s 10b5-1 plan, which allows insiders to schedule trades in advance under preset conditions. Such plans are commonly used to reduce concerns that trades are being made on the basis of material nonpublic information. The document excerpt does not provide Waddill’s beneficial ownership after the reported transactions. The filing was signed on June 25, 2026, by Matthew Gosling as attorney-in-fact for William D. Waddill.